IP Verse

Boehringer Ingelheim International Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Boehringer Ingelheim International Gmbh

Patent Number:
EP3165600
Title:
Cell Culture Medium Comprising Small Peptides
Applicant:
LIFE TECHNOLOGIES CORPORATION
Opposition Date:
Aug 1, 2023
Patent Number:
EP3874047
Title:
Carbon-Source Regulated Protein Production In A Recombinant Host Cell
Applicant:
LONZA LTD.
Opposition Date:
Jan 9, 2023
Patent Number:
EP3342786
Title:
Anti-Dll3 Antibody
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Mar 22, 2022
Patent Number:
EP3541387
Title:
Dose And Regimen For Hdm2-P53 Interaction Inhibitors
Applicant:
NOVARTIS AG
Opposition Date:
Jan 20, 2022
Patent Number:
EP3177645
Title:
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer
Applicant:
LINDHOFER, HORST, DR.
Opposition Date:
Nov 16, 2021
Patent Number:
EP3160463
Title:
Intermittent Dosing Of Mdm2 Inhibitor
Applicant:
NOVARTIS AG
Opposition Date:
Jul 16, 2021
Patent Number:
EP2820151
Title:
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status
Applicant:
IRM LLC
Opposition Date:
Dec 15, 2020
Patent Number:
EP2847223
Title:
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The Same
Applicant:
TRUSTEES OF DARTMOUTH COLLEGE
Opposition Date:
Dec 20, 2019
Patent Number:
EP2647707
Title:
Cytotoxicity-Inducing Therapeutic Agent
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Jun 12, 2019
Patent Number:
EP2530091
Title:
Anti-Dll3 Antibody
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Jan 2, 2019

Latest patents of Boehringer Ingelheim International Gmbh opposed by its competitors

Patent:
EP2313087
Grant Date:
Nov 22, 2023
Title:
Pharmaceutical Dosage Form For Immediate Release Of An Indolinone Derivative
Oppositions:
3
Patent:
EP3110449
Grant Date:
Jun 28, 2023
Title:
Medical Use Of A Dpp-4 Inhibitor
Oppositions:
5
Patent:
EP3802922
Grant Date:
Apr 26, 2023
Title:
Novel Immune Checkpoint Inhibitors
Oppositions:
1
Patent:
EP3362055
Grant Date:
Jan 18, 2023
Title:
Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy
Oppositions:
2
Patent:
EP2482812
Grant Date:
Jan 11, 2023
Title:
Therapeutic Uses Of Pharmaceutical Compositions
Oppositions:
3
Patent:
EP2566469
Grant Date:
Dec 21, 2022
Title:
Combination Therapy
Oppositions:
2
Patent:
EP3517539
Grant Date:
Dec 14, 2022
Title:
Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes
Oppositions:
3
Patent:
EP2849754
Grant Date:
Sep 14, 2022
Title:
A Xanthine Derivative As Dpp-4 Inhibitor For Use In The Treatment Of Sirs And/Or Sepsis
Oppositions:
2
Patent:
EP2981255
Grant Date:
Sep 14, 2022
Title:
Therapeutic Uses Of Empagliflozin
Oppositions:
10
Patent:
EP2397142
Grant Date:
Jul 27, 2022
Title:
Use Of Dpp Iv Inhibitors
Oppositions:
5

Competitors of Boehringer Ingelheim International Gmbh

SANDOZ AG

GENERICS (U.K.) LIMITED

ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.

Want to track Boehringer Ingelheim International Gmbh?

Feel free to send us a message here and we will get back to you